Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrahydrofuran SCHEMBL360933 | 0.81 | ALDH1A1 (0.50) | ALDH1A1 | |
| Tetrahydrofuran SCHEMBL28159237 | 0.79 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL1921973 | 0.79 | ALDH1A1 (0.47) | ALDH1A1 | |
| Chloromethane SCHEMBL28230379 | 0.75 | — | — | |
| Cyclohexane SCHEMBL357093 | 0.75 | ALDH1A1 (0.73) | ALDH1A1 | |
| Magnesium SCHEMBL31402253 | 0.75 | — | — | |
| Tert-Butanol SCHEMBL6023370 | 0.73 | — | — | |
| Dioxane SCHEMBL1921978 | 0.73 | ALDH1A1 (0.57) | ALDH1A1 | |
| Methoxymethane SCHEMBL22118183 | 0.72 | — | — | |
| Ethane SCHEMBL25176936 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004083180-A1 | NOVEL CRYSTALLINE FORMS OF LEVETIRACETAM | HETERO DRUGS LIMITED (IN) | 2004-09-30 | — | — | WO | claimed |
| WO-2024017266-A1 | POLYMORPHIC FORM OF GLP-1R AGONIST, PREPARATION METHOD THEREFOR AND USE THEREOF | 德睿智药(苏州)新药研发有限公司 | 2024-01-25 | — | — | WO | disclosed |
| CN-115385918-A | Novel midazolam crystal form and preparation method thereof | 成都硕德药业有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-8541419-B2 | Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists | ACTIMIS PHARMACEUTICALS, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2328876-B1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTIMIS PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | GB005, INC. | 2011-07-14 | — | — | US | disclosed |
| EP-2328876-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | Actimis Pharmaceuticals, Inc., (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010027448-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | ACTIMIS PHARMACEUTICALS INC. (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20050143445-A1 | Novel crystalline forms of levetiracetam | HETERO DRUGS LIMITED (IN) | 2005-06-30 | — | — | US | disclosed |
| WO-2004083180-A1 | NOVEL CRYSTALLINE FORMS OF LEVETIRACETAM | HETERO DRUGS LIMITED (IN) | 2004-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143445-A1 | Novel crystalline forms of levetiracetam | EPM2A, MAPT, ATG4A | ALDH1A1 2664/4885 |
| US-20110172250-A1 | ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS | HRH2, HRH1, HRH4 | ALDH1A1 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.